Rapid Therapeutic Science Laboratories, Inc. (RTSL) Free Cash Flow (2016 - 2023)
Rapid Therapeutic Science Laboratories' Free Cash Flow history spans 8 years, with the latest figure at -$7325.0 for Q2 2023.
- For Q2 2023, Free Cash Flow rose 97.12% year-over-year to -$7325.0; the TTM value through Jun 2023 reached -$250956.0, up 89.23%, while the annual FY2022 figure was -$1.2 million, 52.4% up from the prior year.
- Free Cash Flow for Q2 2023 was -$7325.0 at Rapid Therapeutic Science Laboratories, up from -$41814.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6868.0 in Q2 2019 and bottomed at -$1.2 million in Q3 2020.
- The 5-year median for Free Cash Flow is -$165414.0 (2022), against an average of -$314835.4.
- The largest annual shift saw Free Cash Flow tumbled 3031.8% in 2020 before it soared 97.12% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$32977.0 in 2019, then tumbled by 309.38% to -$135000.0 in 2020, then plummeted by 308.79% to -$551864.0 in 2021, then skyrocketed by 93.4% to -$36403.0 in 2022, then soared by 79.88% to -$7325.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Free Cash Flow are -$7325.0 (Q2 2023), -$41814.0 (Q1 2023), and -$36403.0 (Q4 2022).